Grifols(OTC) GIFLF

Market Cap$8.00B

Since IPO (2007)-51%

5 Year-52%

1 Year-14%

1 Month+12%

$11.76

+0.00%

+0.00Today

Grifols last closing stock price
Metric	Price	Date
Last close	USD 11.76	2026-08-04

Grifols stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+14.68%	USD 10.25	2026-07-17
1 month	+12.06%	USD 10.49	2026-07-02
3 month	+12.22%	USD 10.48	2026-04-06
Year to date	+1.74%	USD 11.55	2025-11-21
1 year	-13.58%	USD 13.60	2025-07-23
3 year	-15.4%	USD 13.90	2023-07-27
5 year	-52.02%	USD 24.50	2021-08-05
Since inception	-50.96%	USD 23.97	2007-10-19

Grifols Financials at a Glance

Market Cap

$8.00B

Revenue (TTM)

€7.43B

Net Income (TTM)

€452.35M

EPS (TTM)

$0.77

P/E Ratio

15.17

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.76

Volume

144

Open

$11.76

Price

$11.76

Volume

144

Open

$11.76

Previous Close

$11.76

Daily Range

$11.76 - $11.76

52-Week Range

$10.13 - $13.90

Estimated Earnings Date

Nov 10, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$11.76

Volume

144

Open

$11.76

Previous Close

$11.76

Daily Range

$11.76 - $11.76

52-Week Range

$10.13 - $13.90

Estimated Earnings Date

Nov 10, 2026

GIFLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Grifols

Grifols, S.A. is a global healthcare company based in Barcelona, Spain, specializing in the production and sale of therapeutic products derived from blood plasma. Established in 1940, Grifols operates across five main divisions, focusing on innovative solutions for chronic and life-threatening diseases.

Products and Services

Plasma-derived medications for chronic and rare diseases
Non-biological pharmaceutical products and medical provisions
Diagnostic tools for healthcare professionals

Growth Outlook

Revenue growth of 9.5% year-over-year in Q1 2026
Strong demand for immunoglobulins and albumin products
Expansion into emerging markets to drive future growth

Financial Highlights

Q1 2026 net income of €73 million, reflecting a 42% increase
TTM revenue of €7.3 billion, with a gross profit margin of 37.7%
Current ratio of 2.47, indicating strong liquidity position

Grifols, S.A. has established itself as a leader in the healthcare sector, particularly in the field of plasma-derived therapies. The company's diverse product portfolio addresses critical medical needs, catering to a wide range of healthcare providers. Recent financial performance highlights a robust growth trajectory, with significant increases in both revenue and net income. The strong liquidity position further supports Grifols' ability to invest in research and development, ensuring continued innovation and market competitiveness. As the demand for plasma-derived therapies continues to rise, Grifols is well-positioned to capitalize on emerging opportunities in the global healthcare landscape.

AI Generated • Jul 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

25,258

CEO

Nacho Abia Buenache, MBA

Website

www.grifols.com

Headquarters

Barcelona, CT 08174, ES

GIFLF Financials

Key Financial Metrics (TTM)

Gross Margin

37.23%

Operating Margin

16.66%

Net Income Margin

6.09%

Return on Equity

8.43%

Return on Capital

8.29%

Return on Assets

2.25%

Earnings Yield

6.59%

Dividend Yield

0.00%

Payout Ratio

28.31%

Stock Overview

Market Cap

$8.00B

Shares Outstanding

680.58M

Volume

144

Avg. Volume

511.381

Financials (TTM)

Gross Profit

€2.76B

Operating Income

€1.24B

EBITDA

€1.62B

Operating Cash Flow

€1.09B

Capital Expenditure

-€326.77M

Free Cash Flow

€766.75M

Cash & ST Invst.

€529.00M

Total Debt

€8.52B

Grifols Performance Analysis

Grifols annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 6,373,073,574	9.3%
2023	2023-12-31	EUR 7,126,689,189	11.8%
2024	2024-12-31	EUR 7,801,566,940	9.5%
2025	2025-12-31	EUR 8,491,420,500	8.8%

Grifols sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-1.4%
Q4	2025-12-31	6.2%
Q1	2026-03-31	-13.9%
Q2	2026-06-30	9.8%

Grifols annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR 0.32	-1.9%
2023	2023-12-31	EUR 0.07	-79.1%
2024	2024-12-31	EUR 0.25	270.2%
2025	2025-12-31	EUR 0.67	167.2%

Grifols sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	11.8%
Q4	2025-12-31	-26.3%
Q1	2026-03-31	-28.6%
Q2	2026-06-30	130.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€1.87B

-0.9%

Gross Profit

€704.00M

-5.4%

Gross Margin

37.57%

N/A

Market Cap

$8.00B

N/A

Market Cap/Employee

$316.74K

N/A

Employees

25,258

N/A

Net Income

€154.00M

+31.6%

EBITDA

€535.00M

+54.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€529.00M

-6.5%

Total Debt

€8.52B

-3.4%

Accounts Receivable

€1.19B

-5.1%

Inventory

€3.49B

+4.3%

Long Term Debt

€8.10B

-3.9%

Short Term Debt

€420.00M

+6.6%

Return on Assets

2.25%

N/A

Return on Invested Capital

6.93%

N/A

Free Cash Flow

€108.00M

+13.7%

Operating Cash Flow

€227.00M

+46.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ESALFEisai Co., Ltd.

ESALFEisai Co., Ltd.$28.71+0.00%

KYKOFKyowa Kirin Co., Ltd.

KYKOFKyowa Kirin Co., Ltd.$14.43+0.00%

ESAIYEisai Co., Ltd.

ESAIYEisai Co., Ltd.$7.57-0.42%

MTHRYM3, Inc.

MTHRYM3, Inc.$5.18+2.98%

BDUUFBangkok Dusit Medical Services Public Company Limited

BDUUFBangkok Dusit Medical Services Public Company Limited$0.64+0.00%

RCDTFRecordati S.p.A.

RCDTFRecordati S.p.A.$58.00+0.00%

CSPCYCSPC Pharmaceutical Group Limited

CSPCYCSPC Pharmaceutical Group Limited$4.40+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NUNu Holdings

NUNu Holdings$15.36+0.10%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.61-0.00%

INTCIntel

INTCIntel$102.95-0.02%

ONDSOndas

ONDSOndas$9.47+0.06%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$136.75-0.03%

CAPRCapricor Therapeutics

CAPRCapricor Therapeutics$6.46+0.54%

WETOWetour Robotics

WETOWetour Robotics$7.64+1.11%

Questions About GIFLF

What is the current price of Grifols?

Grifols is trading at $11.76 per share.

What is the 52-week range for Grifols?

Over the past 52 weeks, Grifols has traded between $10.13 and $13.90.

How much debt does Grifols have?

As of the most recent reporting period, Grifols reported total debt of €9.74B.

How much cash does Grifols have on hand?

Grifols reported €586.51M in cash and cash equivalents in its most recent financial results.

What is Grifols’s dividend yield?

Grifols does not currently have a dividend yield.

Grifols(OTC) GIFLF

Grifols Financials at a Glance

GIFLF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Grifols

GIFLF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Grifols Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GIFLF

What is the current price of Grifols?

What is the 52-week range for Grifols?

How much debt does Grifols have?

How much cash does Grifols have on hand?

What is Grifols’s dividend yield?

Premium Investing Services